{"id":905405,"date":"2025-11-04T16:40:32","date_gmt":"2025-11-04T21:40:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/"},"modified":"2025-11-04T16:40:32","modified_gmt":"2025-11-04T21:40:32","slug":"inhibrx-announces-participation-in-upcoming-scientific-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/","title":{"rendered":"Inhibrx Announces Participation in Upcoming Scientific Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 4, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Inhibrx Biosciences, Inc. (Nasdaq: INBX) (&#8220;Inhibrx&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg\" title=\"Inhibrx, Inc. logo (PRNewsfoto\/Inhibrx, Inc.)\" alt=\"Inhibrx, Inc. logo (PRNewsfoto\/Inhibrx, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <i><br \/>\n            <span>21<sup>st<\/sup> Annual Industry\/Academia Precision Oncology &amp; Radmed Symposium<br \/><\/span><br \/>\n          <\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i><br \/>\n            <span><br \/>\n              <span class=\"xn-chron\">November 5<\/span><br \/>\n              <sup>th<\/sup>, 2025 \u2013 <span class=\"xn-location\">La Jolla, California<\/span><\/span><br \/>\n          <\/i><br \/>\n        <\/b>\n      <\/p>\n<p class=\"prnml40\">\n        <b><br \/>\n          <span>Title:<\/span><br \/>\n        <\/b><br \/>\n        <span>\u00a0DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma<br \/><\/span><br \/>\n        <b><br \/>\n          <span>Format:<\/span><br \/>\n        <\/b><br \/>\n        <span> Presentation<br \/><\/span><br \/>\n        <b>Presenters:<\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-person\">Josep Garcia<\/span>, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; <span class=\"xn-person\">Katelyn Willis<\/span>, PhD, Director, Biotherapeutics, Inhibrx<br \/><\/span><br \/>\n        <b><br \/>\n          <span>Date:<\/span><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">Wednesday, November 5<\/span><br \/>\n          <sup>th<\/sup>, 2025<br \/><\/span><br \/>\n        <b>Time:<\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">4:45 PM Eastern Standard Time<\/span><br \/>\n          <br \/>\n        <\/span><br \/>\n        <b><br \/>\n          <span>Location:<\/span><br \/>\n        <\/b><br \/>\n        <span>\u00a0 The <span class=\"xn-location\">Alexandria<\/span> at <span class=\"xn-location\">Torrey Pines<\/span>, <span class=\"xn-location\">La Jolla, California<\/span><\/span>\n      <\/p>\n<p>\n        <b><br \/>\n          <i>Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting<br \/><\/i><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <i><br \/>\n            <span class=\"xn-chron\">November 12<\/span><br \/>\n            <sup>th<\/sup> \u2013 15<sup>th<\/sup>, 2025 \u2013 <span class=\"xn-location\">Boca Raton, Florida<\/span><\/i><br \/>\n        <\/b>\n      <\/p>\n<p class=\"prnml40\">\n        <b>Title:<\/b>\u00a0The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study<br \/><b>Lead Author:<\/b>\u00a0Robin L. Jones, MD \u2013 Medical Oncology, The Royal Marsden and Institute of Cancer Research<br \/><b>Format:<\/b> Presentation<br \/><b>Date:<\/b>\u00a0Friday, November 14<sup>th<\/sup>, 2025<br \/><b>Time:<\/b><span class=\"xn-chron\">8:30 AM<\/span> \u2013 <span class=\"xn-chron\">10:00 AM Eastern Standard Time<\/span><br \/><b>Location:<\/b> The <span class=\"xn-location\">Boca Raton<\/span>, <span class=\"xn-location\">Boca Raton, Florida<\/span><\/p>\n<p>\n        <b>Society for NeuroOncology (SNO) 2025 Annual Meeting<br \/><\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">November 19<\/span><br \/>\n          <sup>th <\/sup><br \/>\n          <i>\u2013 <\/i>23<sup>rd<\/sup>, <i>2025 \u2013 <span class=\"xn-location\">Honolulu, Hawaii<\/span><\/i><\/b>\n      <\/p>\n<p class=\"prnml40\">\n        <b>Title:\u00a0<\/b>The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ<br \/><b>Format:\u00a0<\/b>Poster Presentation<br \/><b>Date: <\/b><span class=\"xn-chron\">Saturday, November 22<\/span><sup>nd<\/sup>, 2025<br \/><b>Time: <\/b><span class=\"xn-chron\">4:45 pm<\/span> \u2013 <span class=\"xn-chron\">6:00 PM Eastern Standard Time<\/span><b><br \/>Location:\u00a0<\/b><span class=\"xn-location\">Hawaii<\/span> Convention Center, <span class=\"xn-location\">Honolulu, Hawaii<\/span>; Kamehameha Exhibit Hall II &amp; III<\/p>\n<p>The presentation and poster will be accessible through a link on the investors&#8217; section of Inhibrx&#8217;s website at <a href=\"https:\/\/inhibrxbiosciences.investorroom.com\/events-and-presentations\" rel=\"nofollow\">https:\/\/inhibrxbiosciences.investorroom.com\/events-and-presentations<\/a> upon commencement of each event.<\/p>\n<p>\n        <b>About Inhibrx Biosciences, Inc.<\/b>\n      <\/p>\n<p>Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in <span class=\"xn-chron\">January 2024<\/span> as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences&#8217; current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4549541-1&amp;h=164582554&amp;u=http%3A%2F%2Fwww.inhibrx.com%2F&amp;a=www.inhibrx.com\" target=\"_blank\" rel=\"nofollow\">www.inhibrx.com<\/a>.<\/p>\n<p>\n        <b>Investor and Media Contact:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Kelly Deck<\/span>, CFO<br \/><a href=\"mailto:ir@inhibrx.com\" target=\"_blank\" rel=\"nofollow\">ir@inhibrx.com<\/a><br \/>858-795-4260<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA15414&amp;sd=2025-11-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/inhibrx-announces-participation-in-upcoming-scientific-conferences-302604643.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/inhibrx-announces-participation-in-upcoming-scientific-conferences-302604643.html<\/a><\/p>\n<p>SOURCE  Inhibrx Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA15414&amp;Transmission_Id=202511041601PR_NEWS_USPR_____LA15414&amp;DateId=20251104\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212;\u00a0Inhibrx Biosciences, Inc. (Nasdaq: INBX) (&#8220;Inhibrx&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry\/Academia Precision Oncology &amp; Radmed Symposium November 5 th, 2025 \u2013 La Jolla, California Title: \u00a0DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location: \u00a0 The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Inhibrx Announces Participation in Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905405","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212;\u00a0Inhibrx Biosciences, Inc. (Nasdaq: INBX) (&#8220;Inhibrx&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry\/Academia Precision Oncology &amp; Radmed Symposium November 5 th, 2025 \u2013 La Jolla, California Title: \u00a0DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location: \u00a0 The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting &hellip; Continue reading &quot;Inhibrx Announces Participation in Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T21:40:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Inhibrx Announces Participation in Upcoming Scientific Conferences\",\"datePublished\":\"2025-11-04T21:40:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/\"},\"wordCount\":469,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/\",\"name\":\"Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"datePublished\":\"2025-11-04T21:40:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1063194\\\/inhibrx_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhibrx Announces Participation in Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Nov. 4, 2025 \/PRNewswire\/ &#8212;\u00a0Inhibrx Biosciences, Inc. (Nasdaq: INBX) (&#8220;Inhibrx&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry\/Academia Precision Oncology &amp; Radmed Symposium November 5 th, 2025 \u2013 La Jolla, California Title: \u00a0DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location: \u00a0 The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting &hellip; Continue reading \"Inhibrx Announces Participation in Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T21:40:32+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Inhibrx Announces Participation in Upcoming Scientific Conferences","datePublished":"2025-11-04T21:40:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/"},"wordCount":469,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/","name":"Inhibrx Announces Participation in Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","datePublished":"2025-11-04T21:40:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1063194\/inhibrx_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inhibrx-announces-participation-in-upcoming-scientific-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Inhibrx Announces Participation in Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905405"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905405\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}